Sapience Therapeutics
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
500 Mamaroneck Ave Ste 3200, Harrison, N...Phone Number
(914) 607-6931Website
www.sapiencetherapeutics.comRevenue
$12.4 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Sapience Therapeutics
Sapience Therapeutics is focused on revolutionizing oncology by targeting elusive oncogenic proteins to develop innovative peptide therapeutics. Their product pipeline includes SPEARs and SPARCs, with two lead candidates, lucicebtide (ST101) and ST316, currently in Phase 2 clinical trials. The company aims to provide precision therapies that offer hope to patients and their families facing challenging cancer diagnoses. Their intended clients include patients with various types of cancer, particularly those with conditions like glioblastoma and familial adenomatous polyposis.Explore more
Sapience Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sapience Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Sapience Therapeutics
Check out if Sapience Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Sapience Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Sapience Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Sapience Therapeutics had a recent Job posting/layoffs
Check if Sapience Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Sapience Therapeutics recently announced quarterly report
Sapience Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Sapience Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Sapience Therapeutics
Compare insights from companies similar to Sapience Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Sapience Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sapience Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sapience Therapeutics.
Sapience Therapeutics financials insights
Gather financial insights about Sapience Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$22.5M
2020
Debt
$150K
Sapience Therapeutics Tech Stack
A closer look at the technologies used by Sapience Therapeutics
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Project
received an award of $1,362,268 on May 1, 2023 by HHS NIH with an award end date of April 30, 2025. This award will support efforts focused on advancing ST316, a novel ?-catenin antagonist peptide, through IND-enabling toxicology and pharmacology studies to assess its safety, efficacy, and impact on tumor microenvironment in cancer therapy..
Pharmaceuticals, Clinical Operations, Operations
Event
Events
New Hire
Executive Move
Sapience Therapeutics News & Media
Sapience Therapeutics Presents First Clinical Results from Phase 2 Study of ST316, First-in-Class β-catenin Antagonist, in Second-Line Colorectal Cancer at the American Association for Cancer Research (AACR) Annual Meeting 2026
Highly encouraging initial clinical results in second-line colorectal cancer (2L CRC): 47% objective response rate, disease control in 93% of patients TARRYTOWN, N.Y., April 20, 2026 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the...Sapience Therapeutics Announces Participation in the 25th Annual Needham Virtual Healthcare Conference
TARRYTOWN, N.Y., April 13, 2026 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today announced its participation at the...Sapience Therapeutics Provides Data Update from Phase 2 Trial of Lucicebtide in Patients with Glioblastoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
-Clinical benefit and favorable safety profile as monotherapy and in combination with SOC- -Biomarker data supports MOA: decreased GBM mesenchymal signature and increased TME immune activity- TARRYTOWN, N.Y., June 2, 2025 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage...Sapience Therapeutics Presents ST316 Phase 1 Dose Escalation Data at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium
TARRYTOWN, N.Y., Jan. 27, 2025 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today announced that it presented Phase 1...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sapience Therapeutics
Sign Up For FreeTo access detailed company insights
Sapience Therapeutics is focused on revolutionizing oncology by targeting elusive oncogenic proteins to develop innovative peptide therapeutics. Their product pipeline includes SPEARs and SPARCs, with two lead candidates, lucicebtide (ST101) and ST316, currently in Phase 2 clinical trials. The company aims to provide precision therapies that offer... Read More
